content

Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers

Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of...

Pistoia Alliance Bridges the Gap Between User Experience and Digital Transformation with New Set of Heuristics

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, published a set of nine heuristics for user...

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Degrader ARV-471

Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTACยฎ (PROteolysis TArgeting Chimera) estrogen receptor protein...

AstraZeneca’s Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern

Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published...

Labcorp To Offer First And FDA-Cleared Test For Monitoring Residual Blood Cancer Cells During And After Treatme

Labcorp, a leading global life sciences company, announced that it is now offering clonoSEQยฎ, the first U.S. Food and Drug Administration (FDA)-cleared test that...

AstraZeneca Small-Cell Lung Cancer Treatment Imfinzi Approved in China

AstraZeneca PLC said that its Imfinzi immunotherapy treatment for extensive-stage small-cell lung cancer has been approved in China for first-line treatment of adult patients,...

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer enabled therapeutics

Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, announce a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read